MedTrace Logo

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

NCT04644016 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2026-03-13

No results posted yet for this study

Summary

This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

Conditions

  • AML
  • ALL
  • MDS
  • MPD Withou Myelofibrosis
  • NHL or HL
  • Inherited Metabolic Disorders
  • Hemoglobinopathies
  • Bone Marrow Failure
  • HLH

Interventions

DRUG

Clofarabine

Clofarabine

DRUG

Fludarabine

Fludarabine

DRUG

Busulfan

Busulfan per PK

DRUG

Cyclosporine-A

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

DRUG

Mycophenolate Mofetil

GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

BIOLOGICAL

Cord Blood Graft

The CB graft will be infused on day 0 per standard practice

Sponsors & Collaborators

Principal Investigators

  • Maria Cancio, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2026-12-20
Completion
2026-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04644016 on ClinicalTrials.gov